The utility of a tissue slice model system to determine breast cancer infectivity by oncolytic adenoviruses

Journal of Surgical Research

Volumn 163, Issue 2, 2010, Pages 270-275

  Pennington, Krista ^a   Chu, Quyen D ^a   Curiel, David T ^c   Li, Benjamin D L ^a,b   Mathis, J Michael ^b  

^a Louisiana State University Health Sciences Center   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

adenovirus; breast cancer; CAR; CD46; oncolytic; tissue slice model

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; MEMBRANE COFACTOR PROTEIN; ONCOLYTIC ADENOVIRUS; RED FLUORESCENT PROTEIN; VIRUS PROTEIN; CD46 PROTEIN, HUMAN; CXCR4 PROTEIN, HUMAN; PHOTOPROTEIN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLUORESCENCE MICROSCOPY; GENE DOSAGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SEROTYPE; TISSUE SLICE; VIRION; VIRUS GENOME; VIRUS INFECTION; VIRUS INFECTIVITY; VIRUS REPLICATION; WILD TYPE; ADENOVIRIDAE; BREAST NEOPLASMS; GENETICS; MIDDLE AGED; ONCOLYTIC VIROTHERAPY; PHYSIOLOGY; VIRAL TROPISM; VIROLOGY;

ADENOVIRIDAE; ADULT; AGED; ANTIGENS, CD46; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUMINESCENT PROTEINS; MIDDLE AGED; ONCOLYTIC VIROTHERAPY; RECEPTORS, CXCR4; VIRAL TROPISM; VIRUS REPLICATION;

EID: 77956931305     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2010.03.072     Document Type: Article

References (20)

1. Rein DT, Breidenbach M, Curiel DT. Current developments in adenovirus-based cancer gene therapy. Future Oncol 2006;2:137.
2. Alemany R, Balagué C, Curiel DT. Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000;18:723.
3. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med 2001;7:781.
4. Rancourt C, Rogers BE, Sosnowski BA, et al. Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin Cancer Res 1998;4:2455.
5. StermanDH, Treat J, Litzky LA, et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998;9:1083.
6. Vasey PA, Shulman LN, Campos S, et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 2002;20:1562.
7. Kim M, Zinn KR, Barnett BG, et al. The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur J Cancer 2002;38:1917.
8. Okegawa T, Li Y, Pong RC, et al. The dual impact of Coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. Cancer Res 2000;60:5031.
9. Haviv YS, Blackwell JL, Kanerva A, et al. Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. Cancer Res 2002;62:4273.
10. Kawakami Y, Li H, Lam JT, et al. Substitution of the adenovirus serotype 5 knob with a serotype 3 knob enhances multiple steps in virus replication. Cancer Res 2003;63:1262.
11. Krumdieck CL, dos Santos JE, Ho KJ. A new instrument for the rapid preparation of tissue slices. Anal Biochem 1980;104:118.
12. Parrish AR, Gandolfi AJ, Brendel K. Precision-cut tissue slices: Applications in pharmacology and toxicology. Life Sci 1995;57:1887.
13. Kirby TO, Rivera A, Rein D, et al. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Clin Cancer Res 2004;10:8697.
14. Stoff-Khalili MA, Stoff A, Rivera AA, et al. Preclinical evaluation of transcriptional targeting strategies for carcinoma of the breast in a tissue slice model system. Breast Cancer Res 2005;7:1141.
15. Sirena D, Lilienfeld B, Eisenhut M, et al. The human membrane cofactor CD46 Is a receptor for species B adenovirus serotype 3. J Virol 2004;78:4454.
16. Kanerva A, Mikheeva GV, Krasnykh V, et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 2002;8:275.
17. Madjd Z, Durrant LG, Pinder SE, et al. Do poor-prognosis breast tumours express membrane cofactor proteins (CD46)? Cancer Immunol Immunother 2005;54:149.
18. He TC, Zhou S, da Costa LT, et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998;95:2509.
19. Le LP, Le HN, Dmitriev IP, et al. Dynamic monitoring of oncolytic adenovirus in vivo by genetic capsid labeling. J Natl Cancer Inst 2006;98:203.
20. Haviv YS, Takayama K, Glasgow JN, et al. A model system for the design of armed replicating adenoviruses using p53 as a candidate transgene. Mol Cancer Ther 2002;1:321.